Evaluation of In vivo Bioactivity of a Mutated Streptokinase
Novelty in Biomedicine,
Vol. 5 No. 2 (2017),
24 Ordibehesht 2017
,
Page 71-77
https://doi.org/10.22037/nbm.v5i2.13694
Abstract
Background: Immunogenicity of Streptokinase, as a thrombolytic drug, has limited its clinical use. Elimination of the amino acid residues that are responsible for immunogenicity while don’t affect the bioactivity of streptokinase is worthy. Recently, we modified the streptokinase through the elimination of 42 amino acids from its’ C-terminal and assessed its bioactivity in vitro. In this study, bioactivity of the mutated-streptokinase determined and compared with those of commercially available streptokinase (Heberkinase) in rabbits with induced blood clot.
Materials and Methods: . Recombinant mutated streptokinase was purified and its lipopolysaccharide contained remove and evaluated by LAL test. Thrombolytic activity of drug was evaluated by rabbit jugular vein as in vivo thrombosis model. The thrombolytic property of the drug was evaluated with determining of D-dimer in plasma.
Results:. The results showed in vivo bioactivity of both truncated and commercial streptokinase (p<0.05). This study showed an important influence of the 42 amino acids of C-terminal in bioactivity of the streptokinase.
Conclusion: Clinical use of the r-streptokinase requires more modification to restore its’ activity in vivo. This product may be a promising choice for clinical use after confirmation of its stability and non-immunogenicity.
- Thrombolysis
- Recombinant streptokinase
- Thrombolytic agent
- Fibrinolytic activity
- Jugular vein
- Clot formation
How to Cite
References
Collen D, Stump D, Gold H. Thrombolytic therapy. Annual review of medicine. 1988;39(1):405-23.
MARDER VJ. The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Annals of internal medicine. 1979;90(5):802-8.
Brogden R, Speight T, Avery G. Streptokinase: a review of its clinical pharmacology, mechanism of action and therapeutic uses. Drugs. 1973;5(5-6):357-445.
Sherry S, Fletcher AP, Alkjaersig N. Fibrinolysis and fibrinolytic activity in man. Physiological reviews. 1959;39(2):343-82.
Huang T-T, Malke H, Ferretti JJ. Heterogeneity of the streptokinase gene in group A streptococci. Infection and immunity. 1989;57(2):502-6.
Davies M, Englert ME, De Renzo E. Interaction of Streptokinase and Human Plasminogen I. Combining of Streptokinase and Plasminogen Observed in the Ultracentrifuge Under a Variety of Experimental Conditions. Journal of Biological Chemistry. 1964;239(8):2651-6.
Welfle K, Pfeil W, Misselwitz R, Welfle H, Gerlach D. Conformational properties of streptokinase—differential scanning calorimetric investigations. International journal of biological macromolecules. 1992;14(1):19-22.
Wu D-H, Shi G-Y, Chuang W-J, et al, Coiled Coil Region of Streptokinase γ-Domain Is Essential for Plasminogen Activation. Journal of Biological Chemistry. 2001;276(18):15025-33.
Boxrud PD, Fay WP, Bock PE. Streptokinase binds to human plasmin with high affinity, perturbs the plasmin active site, and induces expression of a substrate recognition exosite for plasminogen. Journal of Biological Chemistry. 2000;275(19):14579-89.
Tillett WS, Edwards L, Garner R. Fibrinolytic activity of hemolytic streptococci. The development of resistance to fibrinolysis following acute hemolytic streptococcus infections. Journal of Clinical Investigation. 1934;13(1):47.
Brügemann J, van der Meer J, Born VJ, Schaaf Wvd, de Graeff PA, Lie KI. Anti-streptokinase antibodies inhibit fibrinolytic effects of anistreplase in acute myocardial infarction. The American journal of cardiology. 1993;72(5):462-4.
Reed G, Kussie P, Parhami-Seren B. A functional analysis of the antigenicity of streptokinase using monoclonal antibody mapping and recombinant streptokinase fragments. The Journal of Immunology. 1993;150(10):4407-15.
Torrèns I, Ojalvo AG, Seralena A, Hayes O, de la Fuente J. A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic. Immunology letters. 2000;70(3):213-8.
Kazemi B, Seyed N, Shekari P, Bandehpour M, Sharifnia Z, Parivar K. Production of mutant streptokinase recombinant protein. Archives of Clinical Infectious Diseases. 2008;3(4):179-83.
Mobarrez M, Bandehpour M, Salehmoghadam M, Kazemi B. Fibrinolytic activity of recombinant mutant streptokinase. Novelty of Biomedicine. 2015;In press.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. nature. 1970;227(5259):680-5.
Blechova R, Pivodova D. Limulus amoebocyte lysate (LAL) test-An alternative method for detection of bacterial endotoxins. Acta Veterinaria Brno. 2001;70(3):291-6.
Tan B. Guidelines on the Care and Use of Animals for Scientific Purposes. Naional Advisory Committee for Laboratory Animal Research. 2004.
Collen D, Stassen J-M, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. Journal of Clinical Investigation. 1983;71(2):368.
Evans DH. Doppler ultrasound: Physics, instrumentation, and clinical applications: John Wiley & Sons; 1989.
Bounameaux H, Slosman D, De Moerloose P, Reber G. Diagnostic value of plasma D-dimer in suspected pulmonary embolism. The Lancet. 1988;332(8611):628-9.
Mahaffey KW, Granger CB, Collins R, et al, Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. The American journal of cardiology. 1996;77(8):551-6.
Parhami-Seren B, Lynch M, White HD, Reed GL. Mapping the antigenic regions of streptokinase in humans before and after streptokinase therapy. Molecular immunology. 1995;32(10):717-24.
Folts JD. Drugs for the prevention of coronary thrombosis: From an animal model to clinical trials. Cardiovascular drugs and therapy. 1995;9(1):31-43.
Clozel J, Tschopp T, Luedin E, Holvoet P. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. Circulation. 1989;79(1):125-33.
Johnstone MT, Botnar RM, Perez AS, et al, In vivo magnetic resonance imaging of experimental thrombosis in a rabbit model. Arteriosclerosis, thrombosis, and vascular biology. 2001;21(9):1556-60.
- Abstract Viewed: 452 times
- PDF Downloaded: 314 times